Trxade Health Intrinsic Value Calculation – TRXADE Group Reports In-Line EPS But Revenue Misses by $0.41M
May 17, 2023
Trending News 🌧️
The company reported a GAAP earnings per share of -$0.03, which was in line with expectations; however, the revenue of $2.25M was below estimates by $0.41M. TRXADE HEALTH ($NASDAQ:MEDS) is a vertically integrated pharmaceutical services company that focuses on providing access to prescription medications for self-insured employers, employees, and individuals. Through its web-based pharmacy platform and its nationwide network of pharmacies, the company offers a full suite of services to help control costs, improve patient outcomes, and provide full transparency throughout the process. The company also provides an integrated marketplace for healthcare industry participants to interact, negotiate, and transact in real-time.
Share Price
TRXADE HEALTH, a leading healthcare technology provider, reported earnings per share (EPS) in-line with analysts’ expectations on Monday, but revenue fell short of estimates by $0.41 million. The company opened the trading day at $0.4, up slightly from its previous closing price of $0.4, and closed the day at the same level. Overall, the stock was up 2.8% from its previous close. The company’s revenues fell short of expectations due to weaker-than-expected demand for its products, despite strong customer growth.
Additionally, despite positive EPS results, investors were disappointed by the revenue miss and the stock price reflected this sentiment. Overall, the stock was up 2.8% from its previous close, suggesting that investors are still confident in the company’s long-term outlook. TRXADE HEALTH remains committed to providing innovative healthcare solutions and is well-positioned for future growth and success. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Trxade Health. More…
| Total Revenues | Net Income | Net Margin |
| 11.45 | -3.47 | -23.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Trxade Health. More…
| Operations | Investing | Financing |
| -1.53 | -0.43 | -0.04 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Trxade Health. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.71 | 3.37 | 0.08 |
Key Ratios Snapshot
Some of the financial key ratios for Trxade Health are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 15.5% | – | -31.2% |
| FCF Margin | ROE | ROA |
| -17.3% | -206.6% | -60.2% |
Analysis – Trxade Health Intrinsic Value Calculation
At GoodWhale, we have conducted an analysis of TRXADE HEALTH‘s fundamentals and arrived at the fair value of its share, which is around $2.3. This valuation was calculated using our proprietary Valuation Line. Currently, TRXADE HEALTH is trading at $0.4 per share, which suggests that the stock is undervalued by 82.9%. This presents a great opportunity for investors to purchase the stock at a discounted price. More…
Peers
It provides a comprehensive solution for medical professionals to efficiently manage their supplies, order medications and compare prices. The company competes in the industry with Jianzhijia Pharmaceutical Chain Group Co Ltd, LifeStance Health Group Inc, and Oriola Corp. Each of these companies offer their own unique products and services to customers in the healthcare industry.
– Jianzhijia Pharmaceutical Chain Group Co Ltd ($SHSE:605266)
Jianzhijia Pharmaceutical Chain Group Co Ltd is a major player in the pharmaceutical industry. The company specializes in the production and sale of pharmaceuticals and related products. As of 2023, the company’s market cap stands at 7.47B, making it one of the larger companies in its sector. Its Return on Equity (ROE) of 14.68% reflects the company’s solid financial performance, indicating a strong return on its shareholders’ equity. The company’s success is further validated through its impressive market capitalization, which has grown significantly since its inception.
– LifeStance Health Group Inc ($NASDAQ:LFST)
LifeStance Health Group Inc is a provider of behavioral health care services. Founded in 2019, the company has grown to become one of the largest behavioral health care providers in the United States. As of 2023, LifeStance Health Group Inc’s market cap stands at 3.18 billion USD, making it one of the most valued companies in the industry. In terms of performance, the company boasts a negative Return on Equity (ROE) of -7.46%, indicating that the company currently is not generating any profits from its investments. The company’s main focus is on providing quality mental and behavioral health services to their customers.
– Oriola Corp ($LTS:0NER)
Oriola Corp is a Finnish public health and wellbeing company founded in 1923 that specializes in pharmaceuticals, medical supplies and consumer health products. With a market cap of 262.37M as of 2023, the company is currently one of the top players in the health and wellbeing sector. Oriola Corp’s Return on Equity (ROE) of 2.64% indicates that they are able to generate a healthy return on their equity investments, further demonstrating their efficiency and ability to achieve financial success.
Summary
TRXADE Health has released its GAAP Earnings Per Share (EPS) of -$0.03, which is in line with expectations. Factors to consider include changes in customer demand, expenses, and market trends. Additionally, investors should assess the company’s current financial situation and operational capacity. By understanding TRXADE Health’s revenue and expenses, investors can make informed decisions about the company’s prospects.
Related Posts
Recent Posts
